Effects of recombinant human endostatin on therapeutic effect, angiogenesis, tumor cell proliferation and migration in patients with non-small cell lung cancer

摘要

Objective:To investigate the effects of recombinant human endostatin on therapeutic effect, angiogenesis, tumor cell proliferation and migration in patients with non-small cell lung cancer.Methods: A total of 100 patients with non-small cell lung cancer treated in our hospital from September 2015 to March 2018 were selected as research subjects.They were randomly divided into observation group and control group, 50 cases in each group.The control group was treated with gemcitabine plus cisplatin, while the observation group was combined with Endostar treatment on the basis of the control group. Observed and compared the expression of the therapeutic effect[including cytokeratin 19 fragment (CYFRA21-1), carcinoembryonic antigen (CEA) and carbohydrate antigen (CA50)], angiogenesis[including vascular endothelial growth factor (VEGF) and hypoxia inducible factor (HIF-1 alpha)], tumor cell proliferation[including insulin-like growth factor (IGF-1) and insulin-like growth factor receptor -7 (IGFBP-7)] and migration[including high mobility group protein AT-hook2 (HMGA2) and high mobility group protein B1 (HMGB1)]in two groups.Results: The two groups showed significant changes in the therapeutic effect, angiogenesis, proliferation and migration of tumor cells. Before treatment, there was no significant difference in all levels between the two groups. After treatment, the levels of CYFRA21-1, CEA, CA50, VEGF, HIF-1a, IGF-1, HMGA2 and HMGB1 in the two groups were significantly lower than those before treatment, while the levels of IGFBP-7 were significantly higher than those before treatment. After treatment, the levels of CYFRA21-1, CEA, CA50, VEGF, HIF-1a, IGF-1, HMGA2 and HMGB1 in the observation group were significantly lower than those in the control group, while the levels of IGFBP-7 were significantly higher than those in the control group. Conclusions: Recombinant human endostatin can enhance the therapeutic effect of non-small cell lung cancer patients, reduce angiogenesis, inhibit tumor cell proliferation and migration